Transforming growth factor–β1 gene transfer ameliorates acute lung allograft rejection  by Mora, Bassem N. et al.
W e have previously reported on the use of liposomalvectors to introduce the chloramphenicol acetyl
transferase reporter gene into transplanted lung iso-
grafts. This was shown to be feasible by means of both
the in vivo1 and ex vivo2 routes of administration.
Transgene expression was noted as early as 4 hours
after ex vivo transfection, under conditions used rou-
tinely in clinical lung transplantation. Although ade-
noviral transfection was also possible in the setting of
experimental lung transplantation,3 we have focused on
the use of cationic lipid vectors due to its resultant
lower toxicity and inflammatory responses in the host
and the possibility of repeated transfection.
An exciting possibility in organ transplantation is the
transfection of immunosuppressive agents to decrease
or prevent acute allograft rejection. Although the ideal
transfection agent has not been found, several recent
reviews have discussed the limitations and potential
Background: The aim of the current work was to study the feasibility of
functional gene transfer using the gene encoding for transforming growth
factor–β1, a known immunosuppressive cytokine, on rat lung allograft func-
tion in the setting of acute rejection.
Methods: The rat left lung transplant technique was used in all experiments,
with Brown Norway donor rats and Fischer recipient rats. After harvest, left
lungs were transfected ex vivo with either sense or antisense transforming
growth factor–β1 constructs complexed to cationic lipids, then implanted
into recipients. On postoperative days 2, 5, and 7, animals were put to death,
arterial oxygenation measured, and acute rejection graded histologically.
Results: On postoperative day 2, there were no differences in acute rejec-
tion or lung function between animals treated with transforming growth
factor–β1 and control animals. On postoperative day 5, oxygenation was
significantly improved in grafts transfected with the transforming growth
factor–β1 sense construct compared with antisense controls (arterial oxy-
gen tension = 411 ± 198 vs 103 ± 85 mm Hg, respectively; P = .002).
Acute rejection scores from lung allografts were also significantly
improved, corresponding to decreases in both vascular and airway rejec-
tion (vascular rejection scores: 2.0 ± 0.5 vs 2.8 ± 0.6; P = .04; airway rejec-
tion scores: 1.3 ± 0.7 vs 2.3 ± 0.8, respectively; P = .02). The amelioration
of acute rejection was temporary and decreased by postoperative day 7.
Conclusions: The feasibility of using gene transfer techniques to introduce
novel functional genes in the setting of lung transplantation is demonstrated.
In this model of rat lung allograft rejection, gene transfer of transforming
growth factor–β1 resulted in temporary but significant improvements in lung
allograft function and acute rejection pathology. (J Thorac Cardiovasc Surg
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advantages of such an approach.4,5 Several candidate
genes have been studied in animal models. These have
included the genes encoding for inducible nitric oxide
synthase,6 adenovirus early region 3,7 antisense inter-
cellular adhesion molecule–1 oligodeoxynucleotides,8
viral interleukin-10,9 and transforming growth fac-
tor–β1 (TGFβ-1).10 These reports have established the
feasibility of whole-organ gene transfection in the set-
ting of acute allograft rejection, resulting in decreases
in acute allograft rejection in recipient animals.
One particularly attractive gene with wide-ranging
immunosuppressive effects is the gene encoding for
TGFβ-1. It is a 25-kd homodimeric peptide whose
amino acid sequence is highly conserved among mam-
malian species. It plays several important roles in
growth, development, inflammation, tissue repair, and
host immunity. There are 3 mammalian isoforms, se-
creted as latent precursors, of which TGFβ-1 is the
most widely studied. It has several immunosuppressive
effects in vitro such as the inhibition of thymocyte pro-
liferation, T- and B-cell proliferation, cytokine produc-
tion, natural killer cell activity, cytotoxic T lymphocyte
development, lymphokine-activated killer cell activity,
helper T-cell type 2 cellular apoptosis, monocyte func-
tion, antibody production, and cell switching.10
In this report, we study the effects and time-course of
gene transfer of the murine TGFβ-1 gene into lung allo-
grafts. A model of acute lung allograft rejection was
developed in the rat in the absence of systemic
immunosuppression. This model was used to study the
effects of TGFβ-1 transfection on acute lung allograft
rejection in the setting of a major histocompatibility
mismatch. The ex vivo technique was chosen since it
was more clinically relevant for organ transplantation
and resulted in higher organ specificity than in vivo
transfection, as we have recently reported.11
Material and methods
Animals. Inbred male Brown Norway donor rats and
Fischer/F344 recipient rats, weighing 270 to 300 g, were used
in all experiments (Charles River Laboratories, Wilmington,
Mass). All animal protocols were approved by the Animal
Studies Committee at Washington University. Animals
received humane care in compliance with the “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996.
Experimental groups. All experiments involved left lung
transplantation with Brown Norway rats used as donors and
Fischer rats as recipients. Animals were transfected with
either the sense or antisense TGFβ-1 construct and then put to
death at 3 different time points after the operation: on post-
operative days (PODs) 2, 5, and 7. The sense TGFβ-1 group
consisted of 3, 8, and 5 animals put to death on PODs 2, 5,
and 7, respectively. The antisense TGFβ-1 group consisted of
4 and 7 animals put to death on PODs 2 and 5, respectively.
Animals put to death on POD 7 included only sense-trans-
fected animals, as previous extensive experience with this
model in our laboratory had invariably resulted in complete
transplant allograft destruction by POD 7 in the absence of
immunosuppression. This was manifested by atelectatic col-
lapse of the transplanted lung, an inability to measure arteri-
al oxygenation from the lung allograft because of the lack of
ventilation of the allograft, and histologic evidence of com-
plete lung destruction. Therefore, no antisense-TGFβ-1 trans-
fected animals were killed beyond POD 5, because neither
lung function nor acute rejection, the end points in this study,
could be measured accurately in the presence of such exten-
sive allograft necrosis and destruction.
TGFβ-1 plasmid-liposome complexes. The naked plas-
mid into which the TGFβ-1 gene was inserted, pMP6A, con-
sisted of an adeno-associated virus left terminal repeat, fol-
lowed downstream by the cytomegalovirus promoter, an
intron sequence, a multiple cloning site, the SV40 polyadeny-
lation tail, then the adeno-associated virus right terminal
repeat. The gene encoding for murine TGFβ-1 is a 1579 base-
pair sequence that bears a high degree of homology to the
native rat TGFβ-1 gene. It was cloned into the multiple
cloning site of the carrier plasmid pMP6A by means of stan-
dard molecular biology techniques. Two plasmids were pro-
duced. One carried the gene in the standard orientation, pro-
ducing functional TGFβ-1 protein and corresponding to the
sense TGFβ-1 plasmid. The other plasmid was identical
except for the TGFβ-1 gene, which was inserted in an inverse
orientation, producing no functional TGFβ-1 protein, and
corresponding to the antisense TGFβ-1 plasmid. Both sense
and antisense TGFβ-1 plasmids were amplified and purified
as previously described.12 The liposomal vector used in these
experiments consisted of GL-67, an amphiphile lipid, mixed
in a 1:2 molar ratio with dioleoylphosphatidylethanolamine.
It was supplied by Genzyme Corporation, Framingham,
Massachusetts,12 and prepared as previously described.1
Rat lung transplantation. An orthotopic left lung rat
transplant model (Brown Norway donors to Fischer/F344
recipients) was performed by a modification of the “cuff
technique” as described in detail elsewhere.2 In brief, after
harvest, an aliquot of 660 µg of plasmid DNA was diluted to
5 mL with normal saline solution and passively flushed into
the left lung graft over 3 to 5 minutes at a pressure of 20 cm
H2O with a silicone catheter inserted into the left pulmonary
vein. The pulmonary venous route of delivery was used for
two reasons. First, we had used this same route of delivery in
previously published experiments in which we used reporter
genes in rat lung grafts.1,2 Second, it was technically easier to
introduce a catheter into the left pulmonary vein rather than
the left pulmonary artery. After storage for 3 hours in normal
saline solution at 4°C, allografts were implanted. In recipi-
ents put to death on PODs 5 and 7, the bronchial anastomo-
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sis was performed with a running 8-0 nylon suture, whereas
the cuff technique was used in animals killed on POD 2. Our
preference in the presence of acute rejection is for the sutured
bronchial anastomosis technique, which was done for the
POD 5 and 7 groups, correlating with the time course of acute
allograft rejection in this model. On POD 2, however, there
was no discernible rejection, which allowed us to use a cuffed
bronchial anastomosis, a superior and easier anastomosis to
perform. The cuffed anastomosis was used for both the sense
and antisense groups on POD 2. When the animals were put
to death and assessed, a median sternotomy was performed
after induction of anesthesia and endotracheal intubation, as
previously described.11 The right hilum was dissected, and
the right pulmonary artery and main stem bronchus were
clamped for 5 minutes, resulting in one-lung ventilation of
the transplanted left lung. This allowed for the measurement
of the overall function of the transplanted left lung with an
inspired oxygen fraction of 100%, a tidal volume of 1.5 mL,
a respiratory rate of 100 breaths/min, and a positive end-expi-
ratory pressure of 1 cm H2O. Recipients were then put to
death and native right and transplanted left lungs were har-
vested. The inferior portion of the lungs was flash-frozen in
liquid nitrogen and stored at –70°C. The superior portion of
the lungs was flushed with formalin and then prepared for
standard hematoxylin-and-eosin histologic staining.
Histologic assessment of allograft rejection. Slides stained
with hematoxylin and eosin were reviewed by a single pathol-
ogist (J.M.R.), who was blinded with respect to the animals
being examined. He has had extensive experience reviewing rat
and human lung allograft rejection.13,14 Histologic rejection
was graded on the basis of the 1996 modification of the work-
ing formulation for the classification of pulmonary allograft
rejection.15 Vascular and airway rejection was scored indepen-
dently. A grade of 0 corresponded to the absence of rejection,
1 to minimal rejection, 2 to mild rejection, 3 to moderate rejec-
tion, and 4 to severe rejection with complete allograft destruc-
tion. Specifically, the following grading schema was developed
and used to assign pathologic rejection scores: For vascular
rejection (A0-A4), a grade of A1 reflected small perivascular
cuffs approximately 2 to 3 cells thick, A2 reflected prominent
perivascular cuffs approximately 3 to 5 cell layers thick or
more but without involvement of adjacent alveoli, A3 reflected
the extension of perivascular cuffing to adjacent alveoli, and
A4 represented confluent inflammation, necrosis, hemorrhage,
and diffuse alveolar damage. For airway rejection (B0-B4), a
grade of B1 represented permeative submucosal airway infil-
trates, B2 represented single-cell epithelial apoptosis with
more extensive submucosal inflammatory infiltrates, B3 repre-
sented additional band-like submucosal infiltrates with more
extensive epithelial cell apoptosis and lymphocytic infiltrates,
and B4 represented ulceration, epithelial denudation, extensive
inflammation, and in some cases airway destruction. The
absence of immunosuppression in this study resulted in more
fulminant rejection than is seen in the clinical setting. As a
result, a large number of the lungs examined had mild to mod-
erate rejection and, as such, were scored as 2 to 3. For statisti-
cal analysis, these were given a grade of 2.5.
Measurement of TGFβ-1 levels. Homogenized lung sam-
ples flash frozen in liquid nitrogen were used to determine
tissue TGFβ-1 levels by means of the plasminogen activator
inhibitor–1 luciferase assay, as previously described.16 Three
separate measurements of luminosity were obtained per sam-
ple, averaged, and then divided by the sample’s weight to
obtain a value of luminosity per gram. This was performed on
the first 5 sense-transfected and first 6 antisense-transfected
lung allografts, in addition to 5 normal lung specimens that
served as a second control for endogenous TGFβ-1 levels.
Given the absence of a difference among these 3 groups, the
remaining lung allografts were not subjected to this assay.
Statistical analysis. All numbers were expressed as mean
± standard deviation. Data were analyzed by means of
Systat version 7 for Windows (Systat, Evanston, Ill). To deal
with unequal variances, the continuous data were log-trans-
formed and separate variance t tests were done where
appropriate. Analysis of variance was performed for 3-
group comparisons. Nonparametric tests were used for the
rejection score data (Mann-Whitney U test). Before com-
pletion of data acquisition, data from the first 4 animals
were analyzed statistically, and additional animals were
added to the TGFβ-1 sense and antisense groups to achieve
greater statistical significance. To deal with this multiple
test problem, the P values obtained were then multiplied by
2 (Bonferroni correction).
Results
This study investigated the feasibility of whole-lung
transfection with a functional gene. There was only 1
death, 24 hours after the operation, which occurred in
the sense TGFβ-1 group that was to have been put to
death on POD 2.
Arterial oxygenation, as sampled from the trans-
planted lung allograft when the animal was put to
death, reflected the functional status of the graft dur-
ing the assessment period since the contralateral right
hilum was clamped. When measured on POD 2, arte-
rial oxygenation was similar in both sense and anti-
sense TGFβ-1 transfected animals: 507 ± 117 versus
449 ± 224 mm Hg for sense and antisense TGFβ-1
transfected animals, respectively (P = .99). On POD
5, arterial oxygenation was significantly higher in ani-
mals transfected with sense TGFβ-1 constructs than
in antisense controls: 411 ± 198 versus 103 ± 85 mm
Hg, respectively (P = .002). On POD 7, arterial oxy-
genation levels from sense TGFβ-1 transfected ani-
mals averaged 64 ± 47, with a range of 0 to 131. One
of the 5 lung allografts in this group could not support
the animal for the requisite 5-minute period of venti-
lation before obtaining the arterial blood gas. This is
contrasted to our previous observations using this
model, when on POD 7, in the absence of immuno-
suppression, the rejecting transplanted lung allografts
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Fig 1.  Histologic cross sections after ex vivo transfection with TGFβ-1. Representative hematoxylin-
eosin–stained cross sections of lung allografts treated with TGFβ-1 sense (A, C, and E) or antisense (B and D)
plasmid-liposome complexes then transplanted and put to death on PODs 2 (A and B), 5 (C and D), or 7 (E).
A and B (POD 2): Minimal perivascular lymphocytic inflammation is present without significant interstitial
airway inflammation. In A, a typical vessel is shown at 3 o’clock, and two adjacent bronchioles are shown at
the 7 o’clock position. In reviewing the entire slide, a rejection score of A2B0 was given for section A and a
score of A2B1 for section B. C and D (POD 5): Increased density of perivascular lymphoid infiltrates and
extensive peribronchiolar inflammation. Airway inflammation is now involving all epithelial layers. After
review of the entire slide, a rejection score of A2-3B2 was given for both sections C and D. E: Extensive acute
rejection with massive cuffing of vessels and airways, with extensive interstitial chronic inflammation, corre-
sponding to a rejection score of A4B3. F: Representative section from the contralateral normal right lung. Note
the absence of inflammation in either airways (at 1-3 o’clock) or vessels (at 5 and 8 o’clock).
A B
C D
E F
could not support the animal for the 5-minute assess-
ment period, resulting in the absence of a measurable
arterial PO2 level.
No noticeable histologic findings were observed on
POD 2 between sense and antisense TGFβ-1 groups, as
evidenced by vascular and airway rejection scores: The
vascular rejection score was 1.5 ± 0.5 versus 1.6 ± 0.3
for the sense and antisense TGFβ-1 groups, respective-
ly (P = .99). The airway rejection score was 0.7 ± 0.6
versus 0.3 ± 0.5 for the sense and antisense TGFβ-1
groups, respectively (P = .6).
On POD 5, gene transfection with sense TGFβ-1
constructs resulted in a significant reduction in the his-
tologic grading of rejection, which was true for both
the vascular and airway rejection scores: The vascular
rejection scores were 2.0 ± 0.5 versus 2.8 ± 0.6 for
sense and antisense TGFβ-1 transfected recipients,
respectively (P = .04). The airway rejection scores
were 1.3 ± 0.7 versus 2.3 ± 0.8 for sense and antisense
TGFβ-1 transfected animals, respectively (P = .02).
On POD 7, the protective effects of TGFβ-1 gene
therapy in this model of acute lung allograft rejection
decreased considerably. This was true for both vascular
and airway rejection, with scores for sense TGFβ-1
transfected animals of 3.7 ± 0.5, and 2.6 ± 0.4, respec-
tively. Although no antisense TGFβ-1 transfected con-
trol animals were put to death on POD 7, our previous
experience with this model had shown extensive
destruction, necrosis, and diffuse alveolar damage by
PODs 6 and 7. Grossly, this was manifested by com-
plete lung destruction, with an inability to inflate or
ventilate the lung allograft. A representative sample of
histologic findings is shown in Fig 1.
Tissue TGFβ-1 levels were measured from lung
homogenates transfected with either sense or antisense
TGFβ-1 constructs by means of the plasminogen acti-
vator inhibitor–1 luciferase assay. This assay yielded a
value of luminosity per gram of tissue, corresponding
to total TGFβ-1 activity: 419 ± 58, 378 ± 118, and 454
± 71 luminosity units per gram for sense TGFβ-1,
antisense TGFβ-1, and normal rat lungs, respectively
(P = .6).
Comment
This report describes the introduction of a novel
functional gene into lung allografts before transplanta-
tion, followed by an observable functional effect after
implantation. The feasibility of whole-lung transfec-
tion with a functional gene is demonstrated, with sub-
sequent amelioration of acute rejection in a model of
fulminant allograft rejection.
The administration of TGFβ-1, or the gene encoding
for it, to organ allografts at the time of transplantation
has been shown to result in beneficial results in several
experimental settings. Initial experiments focused on
the administration of the recombinant TGFβ-1 protein,
which resulted in the prolongation of graft survival in
the mouse heart,17 rat heart,18 mouse pancreatic islet
allografts,19 and rat islet xenografts in mice.20 The
direct injection of naked TGFβ-1 DNA into rat cardiac
allografts significantly prolonged graft survival from
12.6 ± 1.1 days to 26.3 ± 2.5 days in the absence of sys-
temic immunosuppression.10,21 The immunosuppres-
sive effects of TGFβ-1 were shown to be partially
mediated via the suppression of local T-cell immunity.
Specifically, TGFβ-1 gene transfection reduced the
precursor frequency of donor-specific cytotoxic T lym-
phocytes, and both activated and total interleukin-
2–producing helper T lymphocytes in graft-infiltrating
cells.22 More recently, the intracoronary administration
of TGFβ-1 adenoviral vectors in rabbits resulted in the
prolongation of cardiac allograft survival from 6.9 days
to 11.1 days, with significant decreases in rejection
scores in treated animals.23 The introduction of an ade-
noviral vector encoding TGFβ-1 into liver cells before
transplantation has been shown to result in decreased
production of tumor necrosis factor α and γ interfer-
on.24 In another study, a retroviral vector was used to
introduce the TGFβ-1 gene into myoblasts before
transplantation, which resulted in a 20% decrease in
myoblast mortality after 3 days, correlating with lower
neutrophil and macrophage cell counts in transfected
muscles compared with those of control animals.25
Recent evidence from human kidney transplant recipi-
ents suggests that cyclosporine (INN: ciclosporin)
stimulates TGFβ-1 expression, both at the messenger
RNA and protein levels.26 Further, we have recently
reported that the ex vivo administration of TGFβ-1 was
superior to the in vivo approach, resulting in improved
allograft function.11 We have also successfully intro-
duced the TGFβ-1 constructs intratracheally, resulting
in an amelioration of acute rejection, although not to
the same extent as intravenous administration.27 These
data collectively suggest that TGFβ-1 gene transfer is
possible in a transplant setting and results in local,
albeit transient, immunosuppressive effects.
This report further supports the immunosuppressive
role of TGFβ-1 in acute rejection. Significant improve-
ments in arterial oxygenation and acute rejection were
observed after transfection with sense TGFβ-1 con-
structs. On POD 2, arterial oxygenation and acute
rejection scores showed no significant differences
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between the 2 groups. This was not unexpected, as
acute rejection had not yet developed at this time peri-
od, corresponding to normal arterial blood gas mea-
surements and histologic findings from transplanted
lung allografts. In this model, acute rejection was at its
peak on POD 5, with resultant decreases in arterial PO2
measurements in the control (antisense TGFβ-1) group
compared with the experimental (sense TGFβ-1)
group. This correlated with the peak protective effects
of TGFβ-1 gene therapy in this model. The absolute
improvement of arterial oxygenation, such as compar-
ing the function of the transplanted left lung with that
of the native right lung, was not investigated in this
report. It is technically difficult to obtain two arterial
blood gas specimens from the same animal without
exsanguinating the animal. However, on the basis of
our previously published results in isogeneic animals,2
in which acute rejection was not a factor, an arterial PO2
of 546 ± 18 mm Hg had been obtained from trans-
planted left lung isografts by means of techniques sim-
ilar to the ones used in this study. The results obtained
in the sense TGFβ-1 group were still lower than those
obtained in isogeneic controls. The histologic features
of the contralateral native right lungs of recipient ani-
mals were normal compared with findings in the reject-
ing left lung allografts. Thus, although TGFβ-1 result-
ed in an improvement in arterial oxygenation and
histologic rejection scores, it was still not completely
protective against lung dysfunction.
The immunosuppressive effects of TGFβ-1 gene
therapy were transient in our model. By POD 7, the
multifactorial rejection process was able to overcome
the local immunosuppressive effects of TGFβ-1, result-
ing in worsening graft function and pathologic rejec-
tion scores. The model used in these series of experi-
ments corresponded to a major histocompatibility type
I mismatch, which resulted in profound allograft necro-
sis by POD 7. Any prolongation of graft function is
therefore significant, despite transient gene expression.
Another reason for the transient effects of TGFβ-1 gene
therapy includes the small number of transfected cells
typically detected by means of gene therapy tech-
niques, on the order of 5% to 10% of all cells.
TGFβ-1 gene therapy appeared to be more immuno-
suppressive for airway rejection than for vascular rejec-
tion. The exact reason for this gradation in immuno-
suppression is not clear. It should be noted that
although TGFβ-1 plasmid-liposome complexes were
infused via the vascular route, their effect on airway
inflammation was greater than their effect on vascular
rejection.
Finally, when total tissue TGFβ-1 levels were mea-
sured, no significant differences were encountered
between sense and antisense transfected animals. This
is likely due to the measurement of total TGFβ-1 lev-
els using this assay, whereas the functional effect exert-
ed by TGFβ-1 is derived from the active form of the
peptide. The majority of TGFβ-1 is stored in a latent
form, which is also measured by the luciferase assay.
Further, the assay measures endogenous TGFβ-1 levels
present in the rat lung. Additional transfection with
murine TGFβ-1 would not be differentiated from
endogenous rat TGFβ-1. These data support our obser-
vations that tissue TGFβ-1 levels were not different
when measured by another technique, the enzyme-
linked immunosorbent assay, as we have recently
reported.14 It should be noted, however, that by using
reverse transcriptase polymerase chain reaction (RT-
PCR), we have proof of gene transfection with TGFβ-
1 with significant differences found between sense-
transfected animals compared with antisense
controls.27
In summary, gene transfer of TGF-β1 into rat lung
allografts before transplantation resulted in statistically
significant improvements in graft function and acute
rejection. The feasibility of gene transfer with a func-
tional gene in the lung transplant setting is demonstrat-
ed. This may make it possible one day to alter the lung
allograft before or after allograft implantation and
observe beneficial downstream effects such as decreas-
es in ischemia-reperfusion injury or acute and chronic
allograft rejection or even the induction of tolerance.
We thank Richard Schuessler, PhD, for assistance in the
statistical analysis, Kathleen Grapperhaus for performing
hematoxylin-and-eosin staining on pathologic specimens,
and Matthew Bernstein and Mitchell Botney, MD, for assis-
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R E F E R E N C E S
1. Boasquevisque CHR, Lee TC, Mora BN, et al. Liposome-medi-
ated gene transfer to lung isografts. J Thorac Cardiovasc Surg
1997;114:783-92.
2. Boasquevisque CHR, Mora BN, Bernstein M, et al. Ex vivo lipo-
some-mediated gene transfer to lung isografts. J Thorac
Cardiovasc Surg 1998;115:38-44.
3. Boasquevisque CHR, Mora BN, Lee TC, et al. Ex vivo adenovi-
ral-mediated gene transfer to lung isografts during cold preserva-
tion. Ann Thorac Surg 1997;63:1556-61.
4. Wood KJ. Gene therapy and allotransplantation. Curr Opin
Immunol 1997;9:662-8.
5. Knechtle SJ, Zhai Y, Fechner J. Gene therapy in transplantation.
Transplant Immunol 1996;4:257-64.
6. Shears LL, Kawaharada N, Tzeng E, et al. Inducible nitric oxide
synthase suppresses the development of allograft arteriosclerosis.
J Clin Invest 1997;100:2035-42.
7. Efrat S, Fejer G, Brownlee M, Horwitz MS. Prolonged survival
of pancreatic islet allografts mediated by adenovirus immunoreg-
ulatory transgenes. Proc Natl Acad Sci U S A 1995;92:6947-51.
918 Mora et al The Journal of Thoracic and
Cardiovascular Surgery
May 2000
8. Poston RS, Ennen M, Pollard J, Hoyt EG, Billingham ME,
Robbins RC. Ex vivo gene therapy prevents chronic graft vascu-
lar disease in cardiac allografts. J Thorac Cardiovasc Surg
1998;116:386-96.
9. Drazan KE, Wu L, Olthoff KM, Jurim O, Busuttil RW, Shaked A.
Transduction of hepatic allografts achieves local levels of viral
IL-10 which suppress alloreactivity in vitro. J Surg Res
1995;59:219-23.
10. Qin L, Chavin KD, Ding Y, et al. Gene transfer for transplanta-
tion: prolongation of allograft survival with transforming growth
factor-β1. Ann Surg 1994;220:508-19.
11. Boasquevisque CHR, Mora BN, Boglione M, et al. Liposome-
mediated gene transfer in rat lung transplantation: a comparison
between the in vivo and ex vivo approach. J Thorac Cardiovasc
Surg 1999;117:8-15.
12. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of struc-
tures and formulations of cationic lipids for efficient gene trans-
fer to the lung. Hum Gene Ther 1996;7:1701-17.
13. Shiraishi T, DeMeester SR, Worrall NK, et al. Inhibition of
inducible nitric oxide synthase ameliorated rat lung allograft
rejection. J Thorac Cardiovasc Surg 1995;110:1449-60.
14. Yano M, Mora BN, Ritter JK, et al. Ex vivo transfection of trans-
forming growth factor-β1 gene to pulmonary artery segments in
lung grafts. J Thorac Cardiovasc Surg 1999;117:705-13.
15. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990
working formulation for the classification of pulmonary allograft
rejection: Lung Rejection Study Group. J Heart Lung Transplant
1996;15:1-15.
16. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB.
An assay for transforming growth factor-beta using cells trans-
fected with a plasminogen activator inhibitor-1 promoter-
luciferase construct. Anal Biochem 1994;216:276-84.
17. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA.
Immunoregulatory role of transforming growth factor beta (TGF-
beta) in development of killer cells: comparison of active and
latent TGF-beta 1. J Exp Med 1990;172:1777-84.
18. Raju GP, Belland SE, Eisen HJ. Prolongation of cardiac allograft
survival with transforming growth factor-β1 in rats.
Transplantation 1994;48:392-6.
19. Gill RG. Transforming growth factor beta prevents islet allograft
rejection. Transplant Proc 1991;23:747-8.
20. Carel JC, Schreiber RD, Falqui L, Lacy PE. Transforming growth
factor beta decreases the immunogenicity of rat islet xenografts
(rat to mouse) and prevents rejection in association with treat-
ment of the recipient with a monoclonal antibody to interferon
gamma. Proc Natl Acad Sci U S A 1990;87:1591-5.
21. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively
achieve gene transfer in a murine cardiac transplantation model:
immunosuppression with TGF-beta 1 or vIL-10. Transplantation
1995;59:809-16.
22. Qin L, Ding Y, Bromberg JS. Gene transfer of transforming
growth factor-β1 prolongs murine cardiac allograft survival by
inhibiting cell-mediated immunity. Hum Gene Ther
1996;7:1981-8.
23. Brauner R, Nonoyama M, Laks H, et al. Intracoronary aden-
ovirus-mediated transfer of immunosuppressive cytokine genes
prolongs allograft survival. J Thorac Cardiovasc Surg
1997;114:923-33.
24. Drazan KE, Olthoff KM, Wu L, Shen XD, Gelman A, Shaked A.
Adenovirus-mediated gene transfer in the transplant setting: early
events after orthotopic transplantation of liver allografts express-
ing TGF-beta1. Transplantation 1996;62:1080-4.
25. Merly F, Huard C, Asselin I, Robbins PD, Tremblay JP. Anti-
inflammatory effect of transforming growth factor-beta1 in
myoblast transplantation. Transplantation 1998;65:793-9.
26. Shin GT, Khanna A, Ding R, et al. In vivo expression of trans-
forming growth factor-beta1 in humans: stimulation by
cyclosporine. Transplantation 1998;65:313-8.
27. D’Ovidio F, Yano M, Bitter JH, et al. Endobronchial transfection
of naked TGF-β1 DNA attenuates acute lung rejection. Ann
Thorac Surg 1999;68:1008-13.
Discussion
Dr Verdi DiSesa (Chicago, Ill). To say that this is func-
tional gene transfer, you have to show that you are actually
expressing the gene that you transferred. Have you looked for
expression of the gene and do you hypothesize that the rea-
son rejection occurs is that you lose expression of the gene? 
Second, therapy that delays the onset of rejection usually
will enhance the survival of the allograft, but your allografts
were pretty much gone by POD 7 no matter what you did. Do
you know the reason for that? 
Dr Mora. Thank you, Dr DiSesa. We did not include data
on TGFβ-1 gene expression in this presentation because of
time constraints. We have recently used RT-PCR to document
TGFβ-1 gene expression by the production of the TGFβ-1
messenger RNA in transfected allografts. The RT-PCR exper-
iments were carried out with the use of the same TGFβ-1
plasmid described in this report, except that the route of plas-
mid administration was via the airways as opposed to the left
pulmonary vein, as in this report. We also attempted to mea-
sure TGFβ-1 protein levels using both a luciferase assay and
an enzyme-linked immunosorbent assay but did not find sig-
nificant differences between the sense and antisense groups.
One reason for this could be that the protein assays currently
available measure total TGFβ-1. The active form of TGFβ-1
that results in a functional effect, and that was presumably
transferred by the plasmid vectors, represents a small per-
centage of this TGFβ-1 protein pool, where the majority of
TGFβ-1 is stored in a latent, nonfunctional form. Thus a
small increase in active TGFβ-1 would result in an even
smaller effect on total TGFβ-1 levels, presumably below the
levels of detection by the assays.
With regard to your second question concerning graft loss
despite TGFβ-1 transfection, we think this is due to the mul-
tifactorial process involved in acute rejection. Thus, although
one pathway of the rejection cascade may be suppressed by
TGFβ-1 gene transfer, other pathways remain intact and
result in the continuation of rejection.
Dr Beat H. Walpoth (Bern, Switzerland). Do you think
repetition of TGFβ-1 gene transfer would help in postponing
allograft rejection? How are the kinetics of TGFβ-1 gene
transfer? 
Second, is aerosol administration feasible? Perhaps that
will be the best method to use in lung transplantation.
Dr Mora. Thank you. With regard to your first question,
we have not attempted to readminister plasmid-liposome
complexes in these animals. Repeated transfection with plas-
mids could potentially be easily done since liposomal vectors
do not incite a host inflammatory response, as opposed to
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adenoviral vectors. One can theoretically administer the plas-
mid-liposome complexes at various time points in the rejec-
tion process, although we have not looked at this using
TGFβ-1. When we used the chloramphenicol acetyl trans-
ferase reporter gene and did repeated injections in our rat
lung transplant model, we did notice prolonged gene expres-
sion of the chloramphenicol acetyl transferase protein up to
77 days after initial administration. With repeated administra-
tion, there was continued expression of the gene.
With regard to your second question regarding aerosol
administration, one of our fellows in the laboratory is actually
performing that study; he is administrating the TGFβ-1 plasma
DNA, with or without the liposome, intratracheally at the time
of organ procurement. He has observed an amelioration of allo-
graft rejection and an improvement in arterial oxygenation.
Interestingly, the amount of allograft rejection was slightly
worse with an intratracheal route of administration compared
with the intravascular route as described in the current study.
Dr Harvey I. Pass (Detroit, Mich.). I appreciate that you
measured the TGFβ levels. Is the antisense the proper control
here? Is there the theoretic possibility that your antisense is
actually interfering with native TGFβ-1 levels in your control
situation so that your effect in your controls is actually worse
than it really is in the actual situation of a negative cassette
control? 
Dr Mora. The antisense TGFβ-1 group consisted of the
same TGFβ-1 gene as in the sense group except that it was
inserted in an inverse sequence in the plasmid vector. This
controls for nonspecific effects of the plasmid or the lipo-
some, while at the same time producing a nonfunctional pro-
tein. We have performed other experiments in the laboratory
using normal saline controls in the same strain combination
used here, and we have uniformly measured a PaO2 on POD
5 between 50 and 80 mm Hg. This is certainly similar to what
we have observed in the antisense TGFβ-1 controls used in
this study.
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